Koretz K, Brüderlein S, Henne C, Möller P
Institute of Pathology, University of Heidelberg, Germany.
Br J Cancer. 1993 Nov;68(5):926-31. doi: 10.1038/bjc.1993.456.
CD59 (protectin) and CD46 (membrane cofactor protein, MCP) are membrane-bound complement regulator proteins which inhibit complement-mediated cytolysis of autologous cells. CD59, a phosphatidyl-inositol-anchored glycoprotein, inhibits the formation of the terminal membrane attack complex (MAC) of complement and was found to be a second ligand for CD2 contributing to T-cell activation. In 20 colorectal normal mucosa samples, in ten adenomas, 71 carcinomas and in ten liver metastases derived thereof, CD59 was inconsistently expressed in the epithelial compartment. In carcinomas CD59 expression in the whole neoplastic compartment was more often found in well- and moderately differentiated tumours. By contrast, focal expression or even complete lack of CD59 was more often found in poorly differentiated tumours (P = 0.021). In addition, carcinomas without metastases at the time of operation (Dukes A/B) more often expressed CD59 in the entire neoplastic population compared to those carcinomas which had already metastasised (P = 0.018). There was no correlation between the mode of CD59 expression in colorectal carcinomas and the tumour type or location. CD46 has C3b/C4b binding and factor-I dependent cofactor activity and is broadly expressed in various cells and tissues. In the epithelial compartment of normal colorectal mucosa, of all adenomas, carcinomas and their liver metastases, CD46 was expressed throughout the epithelial compartment. Since CD46 was consistently expressed in colorectal carcinomas the low expression or even lack of CD59 in a subset of tumours might not lead to critical complement-mediated attack of CD59-negative tumour cells. Regarding CD59 as a natural T-cell ligand involved in cognate T-cell-target-cell interaction, however, loss of CD59 might well be a selection advantage, provided that tumour antigen-mediated T-cell toxicity in colorectal carcinoma exists.
CD59(保护素)和CD46(膜辅因子蛋白,MCP)是膜结合补体调节蛋白,可抑制补体介导的自体细胞溶解。CD59是一种磷脂酰肌醇锚定糖蛋白,可抑制补体终末膜攻击复合物(MAC)的形成,并且被发现是有助于T细胞活化的CD2的第二种配体。在20份结直肠正常黏膜样本、10份腺瘤、71份癌以及由此衍生的10份肝转移瘤中,CD59在上皮区室中的表达不一致。在癌组织中,整个肿瘤区室中的CD59表达更常见于高分化和中分化肿瘤。相比之下,低分化肿瘤中更常出现CD59的局灶性表达甚至完全缺失(P = 0.021)。此外,与已经发生转移的癌相比,手术时无转移的癌(Dukes A/B)在整个肿瘤群体中更常表达CD59(P = 0.018)。结直肠癌中CD59的表达模式与肿瘤类型或位置之间没有相关性。CD46具有C3b/C4b结合和因子I依赖性辅因子活性,广泛表达于各种细胞和组织中。在正常结直肠黏膜、所有腺瘤、癌及其肝转移瘤的上皮区室中,CD46在上皮区室中均有表达。由于CD46在结直肠癌中持续表达,因此一部分肿瘤中CD59的低表达甚至缺失可能不会导致补体介导的对CD59阴性肿瘤细胞的严重攻击。然而,将CD59视为参与同源T细胞 - 靶细胞相互作用的天然T细胞配体,只要结直肠癌中存在肿瘤抗原介导的T细胞毒性,CD59的缺失很可能是一种选择优势。